Increased tumor infiltrating CD8 T-cells have been also shown to be significantly associated with better prognosis in patients with ER negative, HER-2 negative and triple-negative breast cancer subtypes. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.